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Brain metastasis is one of the dangerous consequences of 
breast cancer and is responsible for most deaths from this 
disease. Aberrant function of protein kinases permits the 
uncontrolled outgrowth of cancer cells. We previously observed 
that cyclin-dependent kinase 5 (CDK5) promotes metastasis 
growth in experimental mouse models of brain metastasis 
through affecting the antitumor immunity. Another protein of 
interest is Interferon Regulatory Factor 2 Binding Protein 1 
(IRF2BP1). While there is not much known about this yet, a 
similar protein, Interferon Regulatory Factor 2 Binding Protein 1 
(IRF2BP1) has been known to be an important factor in the 
immune system. From these findings we are interested in 
investigating the relationship between CDK5 and IRF2P1. 
Previous studies have linked a positive relationship between 
IRF2 and the class I major histocompatibility complex (MHC-I). 
[1] Since IRF2BP1 regulated IRF2, we are also interested in 
investigating the relationship between IRF2BP1 and MHC-I and 
its associated proteins.
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Figure 1: CDK5vrelative expression in Cdk5 gene knockdown cells. 
4T1.Br3 and T11.Br1 breast cancer cells were stably transfected with control 
shRNA or shRNA targeting Cdk5. Total RNA was extracted followed by 
cDNA synthesis and RT-qPCR analysis to profile the relative expression of 
Cdk5. Unpaired T test.
INTRODUCTION RESULTS
METHODS
Cell Culture: 4T1.Br3 and T11.Br1 wells were transfected 
independently with a shRNA-control and a shRNA mediated 
knockdown of Cdk5 and Irf2bp1. These cells were then 
cultured in DMEM/F12 (1:1) supplemented with 10% FBS and 
1% Penicillin and Streptomycin.  
RNA Extraction: RNA was extracted from all cells using TRI 
reagent (MRC) and following the TRIZOL RNA Isolation 
Protocol from the W.M. Keck Foundation Biotechnology 
Microarray Resource Laboratory at Yale University.
cDNA Synthesis: RNA from each cell line was converted into 
cDNA using the using iScript™ gDNA Clear cDNA Synthesis 
Kit (Bio-Rad)
qPCR: Synthesized cDNA was used to perform real time 
quantitative PCR using SYBR Green as the florescent dye on 
the Cdk5 cell group in order to confirm whether the shCdk5 
knockdown was performed correctly.  
Protein Extraction: Membrane, Cytoplasmic, and Nuclear 
protein fractions were extracted from cells using the Cell 
Fractionation Kit from Cell Signaling Technology. 
Immunoblot: Immunoblots were run on the 4T1.Br3 and 
T11.Br1 shCdk5 and shCtl cell group on 12% SuperSep™ 
Phos-tag™ gels in order to determine the phosphorylation of 
IRF2BP1 and total IRF2BP1. Control antibodies for this gel 
were β-actin and CDK5. These samples were also run in 
parallel using 12% Bis-Tris Gel, followed by probing with 
IRF2BP1, β-actin, and CDK5 antibodies. 
Figure 2: Phosphorylation of IRF2BP1 in CDK5 knockdown cells. 4T1.Br3 
and T11.Br1 breast cancer cell lines stably transfected with control shRNA or 
shRNA targeting CDK5 were immunoblotted for the indicated proteins. Cells 
were tested for phosphorylation status of IRF2BP1 using 12% SuperSep™ 
Phos-tag™. The samples were also run in parallel using the 12% Bis-Tris Gel 
gel.
Figure 3: mRNA expression of key MHC-I genes in cells with Irf2bp1 
knockdown. 4T1.Br3 and T11.Br1 breast cancer cell lines stably transfected 
with control shRNA or shRNA targeting Irf2bp1 (2 clones). Total RNA was 
extracted followed by cDNA synthesis and RT-qPCR analysis to profile the 
relative expression of key MHC-I genes (H2-k1, H2-d1, B2m, and Nlrc5). 
One-way ANOVA with Dunnett’s post hoc test.
CONCLUSION
CDK5 may phosphorylate IRF2BP1
In immunoblots conducted on 4T1.Br3 and T11.Br1 cells, 
shCDK5 cells displayed less prominent bands 
corresponding to phosphorylated IRF2BP1. In addition, in 
T11.Br1 cells we also observed a shift of pIRF2BP1 
bands indicative of reduced IRF2BP1 phosphorylation 
(Figure 2). This suggests that CDK5 may lead to 
phosphorylation of IRF2BP1.
IRF2BP1 knockdown reduces mRNA expression of 
MHC-I genes 
In qPCR conducted on 4T1.Br3 and T11.Br1 cells, 
shIRF2BP1 clones showed a significant decrease in 
mRNA expression of genes H2-k1, H2-d1, B2m, and 
Nlrc5 (Figure 3). This indicates that IRF2BP1 controls 
MHC-I production in breast cancer cell lines.
Conclusion
Based on these results, shRNA-mediated knockdown of 
Irf2bp1 in breast cancer cells led to a significant 
reduction of key immune-related genes, such as those 
associated with the class I major histocompatibility 
complex (MHC-I): H2-k1, H2-d1, B2m, and Nlrc5. From 
this we believe that CDK5 may alter the expression of 
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